A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)

Recruiting

Phase 1

Phase 2

SBT101A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)

Sponsor:

SwanBio Therapeutics, Inc.

Code:

NCT05394064

Conditions

AMN

AMN Gene Mutation

X-ALD

Eligibility Criteria

Sex: Male

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

SBT101

Imitation Procedure

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-19. This information was provided to ClinicalTrials.gov by SwanBio Therapeutics, Inc. on 2023-09-13.